Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, IBI310, and Surufatinib in High-Grade Neuroendocrine Neoplasms
NCT05165407Phase 2Recruiting
- Sponsor
- Peking University
- Start
- Jul 2022
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, IBI310, surufatinib in Neuroendocrine neoplasm (NEN), sponsored by Peking University. Started Jul 2022; status: recruiting.
02
Drugs
sintilimabIBI310surufatinib
03
Conditions
Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT05165407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165407.